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EFFECT OF APOE ε4 VARIANT ON PROGRESSION FROM 
MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE  
BRAD P. TAYLOR, HANOVER COLLEGE  1
MENTOR: JOHN KRANTZ 
Abstract 
Alzheimer’s disease is a very prevalent and fatal disorder in older adults, and 
Mild Cognitive Impairment is often seen as a precursor to Alzheimer’s 
disease. Alzheimer’s disease is a form of Dementia that is characterized by 
loss of cognitive abilities while aging. It is ultimately fatal. Mild Cognitive 
Impairment is more of an intermediate stage between normal mental decline 
with aging and the more serious decline of dementia. The APOE ε4 gene has 
been shown to be highly correlated with a greater likelihood of acquiring late-
onset Alzheimer’s disease. This study looked to see the effect that the APOE 
ε4 gene has on the rate of brain volume loss (specifically in the hippocampus, 
entorhinal cortex, and cerebral cortex) in patients who transition from Mild 
Cognitive Impairment to Alzheimer’s disease. This was done by comparing 
people, gathered from the Alzheimer’s Disease Neuroimaging Initiative, with 
Mild Cognitive Impairment who test positive for the ε4 allele vs. those with 
Mild Cognitive Impairment who test negative for the ε4 allele, to see which 
group has a faster loss of brain volume to Alzheimer’s disease. My study 
found that testing positive for the ε4 allele led to faster neurodegeneration in 
both people with Mild Cognitive Impairment who converted to Alzheimer’s 
and even those who did not convert to Alzheimer’s. This study is beneficial 
because it could provide further insight into the potential genetic cause of 
Alzheimer’s disease, especially if the study is replicable. It is unique from 
other studies of this nature because it involves a new cohort. 
 The researcher would like to express the deepest gratitude to the following two 1
people; without their help, this project would not be possible: 
First, to Dr. John Krantz, who advised me through this entire process and continues 
to be a great mentor to this day. 
Second, to Dr. Shannon Risacher, who helped teach me about neuroimaging and 
running statistical procedures to understand brain atrophy.
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Introduction 
Dementia is an umbrella term used to describe a group of illnesses that occur 
in the aging process and are associated with the loss of cognitive abilities, 
including memory. The diseases that fall under the category of dementia are 
characterized by the fact that the loss of cognitive abilities is such that it 
interferes significantly with one’s daily life (National Institutes of Health, 
2013). Dementia is life-altering and has major effects on the patient’s health, 
his or her family, and society as a whole. 
 Dementia was not always the major health problem it is today. In recent 
times, people are living significantly longer than they ever did in the past 
(Verbrugge, 1984). A lot of this is because of recent medical advancements 
and increased knowledge of the benefits of diet and exercise. In the past, 
people had the genetic code that would make them more prone to acquiring 
dementia later in life; however, they never acquired the disease because they 
died at an earlier age, likely from another illness that recent medical 
advancements have cured. It is important to note this because it means 
dementia has not been studied as much as some other diseases that have 
been a problem in the past. As future generations continue to live longer and 
longer, dementia will similarly continue to increase in prevalence (Ferri et 
al., 2005). Therefore, it is absolutely vital that researchers look into further 
understanding these diseases.  
 Alzheimer’s disease (AD) is one of the many forms of dementia and is 
characterized by the significant loss of cognitive abilities, primarily memory, 
that it makes one unable to go about one’s daily life. According to the 
Alzheimer’s Association (2014), it is estimated that 5.2 million Americans 
currently have AD. AD has no cure and is 100% fatal. The disease is first 
characterized by short-term memory loss, but progresses to confusion, 
language difficulties, long-term memory loss, and even mood swings. It also 
causes a significant and gradual loss of brain volume (Braak & Braak, 1998). 
Alzheimer’s disease is truly horrifying for the patient and the family and 
friends of the patient who must now witness him or her completely regress 
mentally, forget the past, and basically disappear before their very eyes. An 
example of AD may be someone who seems to lack continuity of conversation. 
The patient may forget a story he just told you merely an hour before and 
proceed to retell the story in its entirety again. This person has experienced 
such a significant degree of memory loss that they can no longer function 
properly in society. However, it should be noted that AD does not strike 
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completely out of the blue; there is thought to be a prodromal stage called 
Mild Cognitive Impairment (MCI). 
 Often times, MCI is seen as a precursor or a warning sign that AD is to 
come (Friedrich, 1999). MCI should best be thought of as an intermediate 
stage between the normal, slight cognitive declines associated with healthy 
aging and the drastic cognitive declines of AD (Petersen, 2009). It is the 
moderate slope of decline that occurs before a sharp drop-off to an AD 
diagnosis. While MCI is a diagnosis of its own and sometimes shows with no 
progression to AD, the majority of patients with MCI slowly progress to AD, 
and for purposes of this study, it is best to think of it as a step on the path to 
AD. When a patient starts to exhibit symptoms of MCI, usually the patient, 
close family, and friends will begin to notice a decline in mental abilities, 
usually memory. An example of someone with MCI may be someone who 
loses their keys on a more frequent basis, such that it moderately, not 
significantly like it does in AD, interferes with daily life. This person is still 
able to function as a part of society. He or she can still get up, get dressed, 
and go to work like before. However, there is a noticeable impairment. Not 
everyone with MCI progresses to AD, but it means one’s chances of 
progressing to Alzheimer’s disease are significantly higher (Boyle, Wilson, 
Aggarwal, Tang, & Bennett, 2006). This begs the question: how are MCI and 
AD diagnosed? 
 These diseases are diagnosed often by neuropsychological tests, which 
are tests of cognitive abilities and basic motor skills (Khachaturian, 1985). 
These include things like basic memory tasks and walking tests, for example. 
Clinical neuropsychologists look for declines in scores from one time to 
another. Participants may come in with different baseline scores, as a result 
of having a more intellectual background, for example, and this is why future 
tests are needed to see if the scores decline. However, most people do not just 
have neuropsychological tests on file. That is why input from family members 
or close friends is often used to first see if a neuropsychological test should be 
administered. For example, a close friend may notice that the patient has 
been forgetting their car keys more frequently than usual and may refer him 
or her to a Clinical neuropsychologist for a test. More recently, brain imaging 
is starting to be used as a means of diagnosis (Chetelat & Baron, 2003). 
Scans from two different times are beneficial to see if neurodegeneration, or 
loss of brain volume, is taking place. The regions primarily affected, and the 
regions I will be focusing on in this study, are the hippocampus and 
entorhinal cortex (due to their roles in memory) and the cerebral cortex (due 
to its density of grey matter, which is where the neurons are) (Du et al., 
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2001). Based on previous research, there appears to be a gene that may 
explain why greater neurodegeneration, and risk of AD, happens in some 
people than others. 
 ApoE is short for Apolipoprotein E. An apolipoprotein is a protein that 
binds lipids to form lipoproteins. It has a role in the central nervous system 
(the brain and spinal cord) to transport cholesterol to neurons via ApoE 
receptors (Yao, 2002). The gene that codes for ApoE is APOE and is mapped 
on chromosome 19 (Olaisen, Teisberg, & Gedde-Dahl, 1982). It has three 
major alleles, which is just an alternate form of the same gene (Corbo, 
Scacchi, 1994). A specific allele (ε4) of this gene (APOE) has been found to be 
strongly correlated with AD. If one has this specific allele (14% do), one’s 
chances of eventually being diagnosed with AD are much higher than if one is 
without this specific allele of the APOE gene (Corder et al., 1993). Of course, 
there are other factors that contribute to progression to AD: fitness, 
education level, degree of sustained-thinking throughout one’s life, and even 
personality traits (The Search, 2014). All of these traits can improve one’s 
chances of not acquiring AD or at least delay the onset of AD. However, that 
is solely focusing on the nurture side of things. My study, on the other hand, 
will be focusing solely on the potential genetic effect of a specific gene 
(APOE). There has been research already conducted on the effect of having 
the APOE ε4 allele on likelihood of acquiring AD, but the effect of having an 
APOE ε4 allele on neurodegeneration and conversion from MCI to AD as 
compared to people without an APOE ε4 allele (they have combinations of the 
two other variants (ε2 or ε3)) is significantly less-studied.  
 The following research questions are then posed: (1) Does being APOE 
ε4 positive lead to greater change in brain volume in people with MCI who 
either did or did not convert to AD as compared to those who are APOE ε4 
negative? Prior research from Dr. Risacher of the Department of Radiology 
and Imaging Sciences at the Indiana University School of Medicine and other 
researchers would suggest that this is likely (Risacher 2009, Risacher 2010). 
Therefore, our hypothesis follows that APOE ε4 positive MCI patients will 
exhibit faster change in brain volume than the APOE ε4 negative patients 
regardless of conversion status and that APOE ε4 group status will be 
significantly correlated with conversion status, potentially in addition to (and 
independent from) the effect ongoing neurodegeneration of crucial brain 
regions.  
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Methods 
PARTICIPANTS 
This is an archival study. The participants come from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database. ADNI was launched in 
2003 by the National Institute on Aging (NIA), the National Institute of 
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug 
Administration (FDA), private pharmaceutical companies and non-profit 
organizations, as a $60 million, 5-year public-private partnership. The 
primary goal of ADNI has been to test whether serial magnetic resonance 
imaging (MRI), positron emission tomography (PET), other biological 
markers, and clinical and neuropsychological assessment can be combined to 
measure the progression of mild cognitive impairment (MCI) and early 
Alzheimer’s disease (AD). Determination of sensitive and specific markers of 
very early AD progression is intended to aid researchers and clinicians to 
develop new treatments and monitor their effectiveness, as well as lessen the 
time and cost of clinical trials.  
 The Principal Investigator of this initiative is Michael W. Weiner, MD, 
VA Medical Center and University of California-San Francisco. ADNI is the 
result of efforts of many co-investigators from a broad range of academic 
institutions and private corporations, and subjects have been recruited from 
over 50 sites across the U.S. and Canada. The initial goal of ADNI was to 
recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. 
To date these three protocols have recruited over 1500 adults, ages 55 to 90, 
to participate in the research, consisting of cognitively normal older 
individuals, people with early or late MCI, and people with early AD. The 
follow up duration of each group is specified in the protocols for ADNI-1, 
ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-
GO had the option to be followed in ADNI-2. Further information can be 
found at http://www.adni-info.org/ and http://adni.loni.usc.edu.  
 Data about longitudinal clinical diagnosis (cognitively normal, MCI, or 
AD) and conversion, APOE genotype data, and structural MRI scans were 
downloaded from the ADNI data repository (http://adni.loni.usc.edu). The 
database has longitudinal brain scans, so we compare one person’s brain 
scans over time and watch how they worsen as the person progresses from 
MCI to AD. There were 454 original patients with MCI who converted to AD 
at some point over a two-year span. 234 of them were APOE ε4 positive, and 
the other 220 participants were either APOE ε4 negative. Subjects ranged 
between 47 and 91 years of age, with the average age being 73.3 years old.  
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PROCEDURE 
Brain scans are gathered by using MRI machines. These work by the fact 
that atoms are spinning in random motion in their own magnetic fields 
(Berger, 2002). When a magnetic field is applied, most atoms either point 
north or south, but some do no line up either way. When a radio frequency 
pulse is applied, these atoms that are not lined up either way, spin the 
opposite direction. When that radio frequency is turned off, the atoms that 
are not lined up return to their original position. This emits energy, which is 
sent to a computer, and that computer converts the signal into an image (i.e. 
a brain scan). These brain scans are completed on all participants and 
archived for analysis in ADNI. 
 After obtaining the brain scans of people from the ADNI, the brains of 
patients with the APOE ε4 allele will be compared against patients without 
the APOE ε4 allele to see if the APOE ε4 allele leads to greater 
neurodegeneration in MCI patients, and increased rate of conversion from 
MCI to late-onset AD. 
MEASURES 
Freesurfer (version 5.1) is a software program that takes the brain image and 
divides it up into the anatomical sub-regions. For regions like the 
hippocampus, the program essentially traces a 3D line around where it 
thinks this structure is based on previous knowledge of structure location and 
landmarks identified in the image. Then it gives you the total volume of the 
structure. For the cortical surface, it estimates the thickness of the grey 
matter across the entire cortex. Then it slices the brain up into different 
anatomical cortical regions and reports the average thickness of the cortex 
across that part of the grey matter. Figure 1 shows a pictorial representation 
of Freesurfer (Desikan et al., 2006; Freesurfer (n.d.)).  
STATISTICS 
Three separate ANCOVA models were used to compare differences in 
annualized percent change (APC) in three brain areas (hippocampal volume, 
entorhinal cortex thickness, and cerebral cortex volume) as a function of 
APOE ε4 carrier status (positive or negative) and two-year conversion status 
(convert to AD or stable at MCI), covaried for age, gender, education, and 
handedness between groups. A logistic regression model was used to assess 
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Figure 1. This image demonstrates how Freesurfer represents different 
brain regions.  
the effect of APOE ε4 carrier status on likelihood of conversion from MCI to 
AD over two years, covaried for age, education, gender, MCI type (early or 
late), and handedness. A second logistic regression model was estimated to 
determine the independent effects of hippocampal atrophy rate and APOE ε4 
carrier status on clinical conversion from MCI to AD over and above age, 
gender, MCI type (early or late), education, and handedness. This second 
logistic regression model was run again for both entorhinal cortex thickness 
atrophy rate and cerebral cortex atrophy rate.  
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Results 
The overall model evaluating the effect of conversion and APOE ε4 carrier 
status on Annual Percent Change (APC) in hippocampal volume that 
included conversion status, APOE ε4 carrier status, and the interaction 
between conversion and APOE ε4 group, as well as age, handedness, 
education, and gender was significant (F (7, 447) = 9.636, p < 0.001). 
Specifically, significant independent main effects of both conversion status (p 
= 0.003) and APOE ε4 carrier status (p = 0.002) were observed, but the 
interaction of APOE ε4 group status by conversion status was non-significant 
(p>0.05). A similar effect was seen on APC in entorhinal cortex thickness, 
with the overall model significant (F(7, 447)=14.428, p<0.001), and significant 
main effects of conversion status (p=0.001) and APOE ε4 group (p=0.002), but 
no interaction (p>0.05). Finally, the same pattern was observed when 
evaluating APC in cerebral cortex volume. The overall model was significant 
(F (7, 447) = 9.478, p < 0.001), with significant main effects of both conversion 
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Figure 2. The effect of APOE ε4 carrier status and Conversion on the Mean 
Annual Percent Change of Hippocampus Volume (in mm3).
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status (p = 0.007) and APOE ε4 group (p = 0.008), but no interaction (p > 
0.05). 
 To see if APOE ε4 carrier status was associated with conversion status 
independent of the APC in hippocampal volume, a logistic regression, 
covaried for education, handedness, baseline diagnostic group, age, and 
gender, was run. APOE ε4 carrier group status was significantly associated 
with conversion status independent of the APC in hippocampal volume (p = 
.007, odds ratio (OR) = 1.926). The APC in hippocampal volume was also 
significantly associated with conversion status independent of the APOE ε4 
carrier status (p < .001, OR = 0.844). Similar analyses were run for the 
impact of APOE ε4 carrier status and APC in entorhinal cortex and cerebral 
cortex volume. APOE ε4 carrier status was significantly correlated with 
conversion status independent of the APC of entorhinal cortex thickness (p = 
0.028, OR = 1.730). The APC in entorhinal cortex thickness was also 
significantly correlated with conversion status independent of the APOE ε4 
carrier status (p < 0.001, OR = 0.795). Finally, APOE ε4 carrier status was 
significantly associated with conversion status independent of APC in 
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Figure 3. The effect of APOE ε4 carrier status and Conversion on the Mean 
Thickness (in mm) Atrophy Rate of the Entorhinal Cortex.
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cerebral cortex volume (p = 0.005, OR = 1.972). The APC in cerebral cortex 
volume was also significantly correlated with conversion status independent 
of the APOE ε4 group status (p < 0.001, OR = 0.767).  
 Figure 2 shows that APOE ε4 positive participants have a greater loss 
of hippocampal volume than APOE ε4 negative participants, whether or not 
one converted to AD from MCI or not. In both conversion conditions (yes and 
no) the APOE ε4 positive patients had significantly more loss of hippocampal 
volume than the APOE ε4 negative patients. There was even a trend for 
slightly more loss of hippocampal volume in the APOE ε4 group positive 
patients who did not convert to AD than those who converted to AD but were 
not APOE ε4 carriers. 
 Figure 3 shows APOE ε4 positive participant have a more significant 
loss of entorhinal cortex thickness than those negative for an APOE ε4 allele 
in either of the conversion conditions. These results are even more 
pronounced than the ones seen for the hippocampus, with the differences 
between the APOE ε4 conditions being even larger. Again, the patients who 
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Figure 4. The effect of APOE ε4 carrier status and Conversion on the Mean 
Annual Percent Change of Cerebral Cortex Volume (in mm3).
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tested positive for the APOE ε4 group allele, and who did not convert to AD, 
still had a trend for slightly greater entorhinal cortex thickness atrophy rate 
than those who actually did convert to AD but who were APOE ε4 negative. 
 Figure 4 shows again APOE ε4 positive participants show more 
significant loss of cerebral cortex volume than those APOE ε4 negative 
participants. Again, the APOE ε4 positive patients who did not convert to AD 
had a trend for slightly more loss of cerebral cortex volume than the APOE ε4 
negative patients who did actually convert to AD.  
Discussion & Conclusion 
My hypothesis that APOE ε4 positive MCI patients would exhibit greater 
atrophy in brain volume (hippocampus, cerebral cortex, and entorhinal 
cortex) regardless of conversion status was confirmed. There is greater 
neurodegeneration in both APOE ε4 positive patients who acquire AD and 
APOE ε4 positive patients who do not acquire AD than APOE ε4 negative 
patients in either group. Further, my hypothesis that APOE ε4 status was 
significantly associated with conversion status independent of 
neurodegeneration of brain regions was also confirmed. In fact, carrying an 
APOE ε4 allele made you approximately two or more times more likely to 
convert to AD, independent of the significant effect of increased atrophy rate 
on conversion (more atrophy = greater rate of conversion). Overall, these 
findings are a prime example of the importance and, in this case, sad role 
that genetics plays in our health.  
 However, even though I have shown that carrying the APOE ε4 allele 
does lead to greater neurodegeneration, the results do not tell us about the 
effects of non-genetic factors such as physical and mental exercise. Physical 
Exercise has already been shown to reduce one’s likelihood of acquiring MCI 
(Geda et al., 2010). Mental Exercise has also been shown to improve the 
episodic memory of MCI subjects (Belleville, Gilbert, Fontaine, Gagnon, 
Ménard, & Gauthier, 2006). However, there have not been many studies done 
on the potential varying levels of effects of physical and mental exercise on 
people who test positive for the APOE ε4 allele versus those who test 
negative for it. Future studies could look to see if there is a greater decrease 
in brain atrophy with the physical and mental exercise intervention in those 
without the APOE ε4 allele versus those who test positive for it. 
 This study was potentially limited by the fact that all the data came 
from people in the United States and Canada. A hot-button issue in modern 
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psychology is the fact that a lot of our data comes from WEIRD (Western, 
Educated people from Industrialized, Rich, and Democratic countries) 
populations. Whereas, a huge chunk of the world’s population is not “WEIRD” 
(Henrich, Heine, & Norenzayan, 2010). Different cultures would likely vary 
with regard to non-genetic factors like levels of exercise, education, and 
general lifestyle. Due to the expensive nature of MRI machines, it makes 
sense that most people who have been tested come from wealthy countries. It 
would be interesting to see how these studies differ in potentially different 
populations.  
 These results also beg the question of whether or not MCI should be its 
own diagnosis or seen only as a precursor to AD. Prior literature lists MCI as 
both a syndrome, in and of itself, and also as a risk state for dementia 
(Gauthier et al., 2006). I believe that these results are supportive of prior 
literature in the sense that MCI can be both its own stand-alone diagnosis 
and a risk state for dementia. Also, the fact that researchers are attempting 
to keep people at MCI and not allow it to progress to AD only reinforces the 
fact that people can stay at MCI. These diseases are certainly interconnected, 
but one should remain hesitant to claim that MCI is definitely going to result 
in AD until further research is done. 
 In sum, APOE ε4 positive MCI patients showed greater rates of 
neurodegeneration regardless of conversion status. Further, APOE ε4 
positive MCI participants showed an approximately two-fold increased risk of 
conversion to AD over two years, independent from the effect of atrophy rate 
on conversion.  
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